Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

7-tert-Butyl-6-(4-Chloro-Phenyl)-2-Thioxo-2,3-Dihydro-1H-Pyrido[2,3-d]Pyrimidin-4-One, a Classic Polymodal Inhibitor of Transient Receptor Potential Vanilloid Type 1 with a Reduced Liability for Hyperthermia, Is Analgesic and Ameliorates Visceral Hypersensitivity

Mark S. Nash, Peter McIntyre, Alex Groarke, Elliot Lilley, Andrew Culshaw, Allan Hallett, Moh Panesar, Alyson Fox and Stuart Bevan
Journal of Pharmacology and Experimental Therapeutics August 2012, 342 (2) 389-398; DOI: https://doi.org/10.1124/jpet.112.191932
Mark S. Nash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter McIntyre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Groarke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliot Lilley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Culshaw
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan Hallett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moh Panesar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alyson Fox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Bevan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 342 no. 2 389-398
DOI 
https://doi.org/10.1124/jpet.112.191932
PubMed 
22566669

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received January 14, 2012
  • Accepted May 4, 2012
  • Published online July 16, 2012.

Article Versions

  • Earlier version (May 7, 2012 - 08:27).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Mark S. Nash,
  2. Peter McIntyre,
  3. Alex Groarke,
  4. Elliot Lilley,
  5. Andrew Culshaw,
  6. Allan Hallett,
  7. Moh Panesar,
  8. Alyson Fox and
  9. Stuart Bevan
  1. Novartis Institutes for BioMedical Research, Horsham, United Kingdom (M.S.N., A.G., E.L., A.C., A.H., M.P., A.F.); Department of Pharmacology, University of Melbourne, Victoria, Australia (P.M.); and Wolfson Centre for Age-Related Diseases, King's College, London, United Kingdom (S.B.)
  1. Address correspondence to:
    Stuart Bevan, Wolfson Centre for Age Related Diseases, King's College London, London SE1 1UL, United Kingdom. E-mail: stuart.bevan{at}kcl.ac.uk
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2012 to March 2023

AbstractFullPdf
May 20122062124
Jun 201232059
Jul 20122561275
Aug 20122081644
Sep 2012102935
Oct 201271616
Nov 2012611120
Dec 201239826
Jan 2013491118
Feb 201353620
Mar 201356920
Apr 2013531210
May 201331715
Jun 2013271220
Jul 201318312
Aug 201314431
Sep 2013291629
Oct 2013171218
Nov 2013998
Dec 2013261313
Jan 2014201316
Feb 20148109
Mar 2014221725
Apr 201417821
May 2014171215
Jun 201472011
Jul 2014262615
Aug 201414177
Sep 2014251020
Oct 201417915
Nov 2014533
Dec 201441114
Jan 201524813
Feb 2015685
Mar 20151098
Apr 2015141115
May 201511179
Jun 2015151111
Jul 201561514
Aug 2015151714
Sep 20151696
Oct 20159166
Nov 201523144
Dec 20152173
Jan 2016141814
Feb 201612711
Mar 20169512
Apr 201611811
May 201651114
Jun 201614523
Jul 201613526
Aug 201614925
Sep 201671116
Oct 201682112
Nov 20167159
Dec 201621910
Jan 20170128
Feb 20171153
Mar 20171294
Apr 2017097
May 20171173
Jun 2017093
Jul 20175148
Aug 2017071
Sep 201732017
Oct 201712215
Nov 201711510
Dec 20177117
Jan 201801310
Feb 201831016
Mar 20180139
Apr 201813313
May 201842313
Jun 20183184
Jul 20181112
Aug 2018045
Sep 20182127
Oct 201801610
Nov 20181126
Dec 2018851
Jan 20191426
Feb 20192123
Mar 20192535
Apr 20194114
May 20191901
Jun 20194912
Jul 20193209
Aug 20196223
Sep 20191712
Oct 20192525
Nov 20192412
Dec 20191502
Jan 20201533
Feb 20202336
Mar 20201000
Apr 20201725
May 20201100
Jun 20201300
Jul 20201212
Aug 2020803
Sep 20202005
Oct 20201111
Nov 20202105
Dec 20203027
Jan 202133113
Feb 20212446
Mar 20213422
Apr 20211121
May 20213736
Jun 20211610
Jul 2021934
Aug 20212015
Sep 20212421
Oct 2021710
Nov 20212110
Dec 20213231
Jan 20221819
Feb 20221032
Mar 20221113
Apr 20222626
May 20221223
Jun 20221410
Jul 20222641
Aug 20222836
Sep 20221114
Oct 20221820
Nov 20221121
Dec 20221412
Jan 20232831
Feb 20231042
Mar 20231101

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 342 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 342, Issue 2
1 Aug 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
7-tert-Butyl-6-(4-Chloro-Phenyl)-2-Thioxo-2,3-Dihydro-1H-Pyrido[2,3-d]Pyrimidin-4-One, a Classic Polymodal Inhibitor of Transient Receptor Potential Vanilloid Type 1 with a Reduced Liability for Hyperthermia, Is Analgesic and Ameliorates Visceral Hyperse…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

BCTP, a TRPV1 Inhibitor with Reduced Hyperthermia

Mark S. Nash, Peter McIntyre, Alex Groarke, Elliot Lilley, Andrew Culshaw, Allan Hallett, Moh Panesar, Alyson Fox and Stuart Bevan
Journal of Pharmacology and Experimental Therapeutics August 1, 2012, 342 (2) 389-398; DOI: https://doi.org/10.1124/jpet.112.191932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNeuropharmacology

BCTP, a TRPV1 Inhibitor with Reduced Hyperthermia

Mark S. Nash, Peter McIntyre, Alex Groarke, Elliot Lilley, Andrew Culshaw, Allan Hallett, Moh Panesar, Alyson Fox and Stuart Bevan
Journal of Pharmacology and Experimental Therapeutics August 1, 2012, 342 (2) 389-398; DOI: https://doi.org/10.1124/jpet.112.191932
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • KRM-II-81 Analogs
  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics